SCHEDULE: Qiming U.S. Healthcare Fund II Reduces Jasper Therapeutics Stake

Qiming U.S. Healthcare Fund II and its affiliates reported a reduced beneficial ownership of 3.3% in Jasper Therapeutics, Inc. as of September 30, 2025.

Summary

• Qiming U.S. Healthcare Fund II, L.P., along with its general partner Qiming U.S. Healthcare GP II, LLC, and managing partners Mark McDade and Gary Rieschel, reported a beneficial ownership of 928,964 shares of Jasper Therapeutics, Inc. Voting Common Stock.
• This represents 3.3% of the company's outstanding shares, based on 27,984,039 shares as of September 30, 2025.
• The filing is an Amendment No. 2, indicating a change from a previously reported position, likely a reduction below the 5% reporting threshold.
• The reporting persons disclaim status as a "group" for purposes of this Schedule 13G.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the implied reduction of a significant institutional stake below the 5% reporting threshold, which can be perceived as a lack of conviction or a strategic divestment.

Negatives

• Qiming U.S. Healthcare Fund II, L.P. and its affiliates have reduced their beneficial ownership in Jasper Therapeutics, Inc. to 3.3%, indicating a divestment of a portion of their previous holdings which were likely above the 5% reporting threshold.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Jasper Therapeutics, Inc. or the reporting persons regarding the company's future performance.

Industry Context

This filing reflects a change in institutional investor positioning within the biotechnology or healthcare sector, where venture capital funds like Qiming U.S. Healthcare Fund II frequently invest in publicly traded companies. A reduction in stake by a notable fund can sometimes signal a shift in investment strategy or outlook for the specific company or sector.

Stakeholder Impact

• Shareholders are informed of a change in a significant institutional investor's position, which may influence market perception and trading activity.

Key Dates

Recommendation

While the reduction in institutional ownership by Qiming U.S. Healthcare Fund II is a negative signal, this Schedule 13G filing alone does not provide sufficient operational or financial details about Jasper Therapeutics, Inc. to warrant a 'sell' recommendation. Investors should 'hold' and await further company-specific news or financial reports to assess the underlying reasons for the divestment and the company's ongoing performance.

Keywords

Jasper Therapeutics, Qiming U.S. Healthcare Fund, institutional ownership, Schedule 13G, beneficial ownership, common stock, investor update